Table I.

Study population characteristics and COVID-19 vaccination outcome

Patient no.	Sex	Age (y)	Index reaction	Index product	Positive skin tests	Post index PS80 exposure	Negative skin test for PS80	COVID-19 vaccine∗
1	M	53	ANA	PEG 3350	PEG: 3350, 4000, 6000	Yes	Not performed	J&J
2	M	67	ANA	PEG 4000	PEG: 4000	Yes	Not performed	J&J
3	F	73	ANA	PEG 4000	PEG: 4000	Yes	Not performed	J&J
4	F	54	U, AE	PEG 400	PEG: 400	Yes	Not performed	J&J
5	F	81	U	PEG 3350	PEG: 400, 4000	Yes	Not performed	AZ
6	M	70	Rash	PEG 3350	PEG: 3350, 4000	Yes	Not performed	AZ
7	F	21	U, AE	PEG 3350	PEG: 3350, 4000, 6000	Yes	Yes	J&J
8	M	39	ANA	PEG 3350	PEG: 3350,† 4000†	Yes	Yes	J&J
9	M	56	ANA	PEG 4000	PEG: 3350, 4000	No	Yes	J&J
10	F	60	ANA	PEG 3350	PEG: 3350,† 4000†	No	Yes	J&J
11	F	69	ANA	PEG 3350	PEG: 3350, 4000, 6000	No	Yes	J&J
12	M	33	ANA	PEG 3350	PEG: 1500, 3350, 4000; PS80	No	No	-
13	M	31	ANA	PEG 6000	PEG: 6000; PS80	No	No	-
14	F	34	ANA	PEG 4000	PS80‡	No	No	-

AE, Angioedema; ANA, anaphylaxis (defined as an immediate reaction involving > 1 organ system [World Allergy Organization]; AZ, AstraZeneca (Vaxzevria) COVID-19 vaccine; J&J, Johnson & Johnson (Janssen) COVID-19 vaccine; U, urticaria.

^∗All COVID-19 vaccinations were tolerated.

^†Systemic reaction during skin testing without positive skin test.

^‡Systemic reaction during skin testing with positive skin test.